Max-Planck-Institut für Kolloid- und Grenzflächenforschung
About MPI für Kolloid- und Grenzflächenforschung
The Max Planck Institute of Colloids and Interfaces was founded in 1992. It is managed on a collegial basis and is divided into the departments of Biomaterials, Biomolecular Systems, Interfaces, Colloid Chemistry and Theory & Bio-Systems. Current research focuses on polymer films, membranes, organic and inorganic nanostructures, microcapsules, biomineralization, nano- and microreactors, molecular motors and filaments as well as the chemistry and biology of carbohydrates. Biomimetic systems are the focus of the scientific work. Based on models from nature, new hierarchical materials and active systems are being researched that can be adaptive, self-healing or self-assembling.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Chemistry
News about MPI für Kolloid- und Grenzflächenforschung
Here you will find Max-Planck-Institut für Kolloid- und Grenzflächenforschung
Last viewed contents
Truffini & Reggè Farmaceutici S.r.l. - Mailand, Italy
Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung (IPK Gatersleben) - Gatersleben, Germany
From beer to useful fats and medicines - The spent grain from beer brewing can be used to make microcapsules that can preserve omega-3 oils and medicines
Simtra BioPharma Solutions - Parsippany, USA
Ancient viral DNA shapes modern human placentas - “It’s a reminder that there is much more to learn about our genome and how ancient infections can influence who we are today”
Chemistry meets biology: controlling artificial cell membranes through catalysis - Researchers develop an artificial metalloenzyme-based platform that enables programmable control of artificial membrane behavior
Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies - Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)
StratifAI Raises €12.5M for Clinical Validation of AI Biomarker Platform for Precision Oncology - Oversubscribed round expand global reach, and unlock multi‑billion‑euro cancer diagnostics market
New deep-learning tool can tell if your salmon is wild or farmed
Recipharm secures major additional grant to develop AI-enabled manufacturing technologies - Development of an AI-enabled simulator and process control platform, to speed up process development, cut costs and improve manufacturing efficiency
